CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody

Michael D. Farwell; Raymond F. Gamache; Hasan Babazada; Matthew D. Hellmann; James J. Harding; Ron Korn; Alessandro Mascioni; William Le; Ian Wilson; Michael S. Gordon; Anna M. Wu; Gary A. Ulaner; Jedd D. Wolchok; Michael A. Postow; Neeta Pandit-Taskar

doi:10.2967/jnumed.121.262485

Research ArticleClinical (Oncology: Other)

CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of ⁸⁹Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody

Michael D. Farwell, Raymond F. Gamache, Hasan Babazada, Matthew D. Hellmann, James J. Harding, Ron Korn, Alessandro Mascioni, William Le, Ian Wilson, Michael S. Gordon, Anna M. Wu, Gary A. Ulaner, Jedd D. Wolchok, Michael A. Postow and Neeta Pandit-Taskar

Journal of Nuclear Medicine May 2022, 63 (5) 720-726; DOI: https://doi.org/10.2967/jnumed.121.262485

Michael D. Farwell

1Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;

2Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Raymond F. Gamache

1Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Hasan Babazada

1Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Matthew D. Hellmann

3Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York;

4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York;

5Department of Medicine, Weill Cornell Medical College, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

James J. Harding

4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York;

5Department of Medicine, Weill Cornell Medical College, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ron Korn

6Imaging Endpoints, Scottsdale, Arizona;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alessandro Mascioni

7ImaginAb, Inc., Inglewood, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

William Le

7ImaginAb, Inc., Inglewood, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ian Wilson

7ImaginAb, Inc., Inglewood, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael S. Gordon

8HonorHealth Research Institute, Scottsdale, Arizona;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Anna M. Wu

7ImaginAb, Inc., Inglewood, California;

9Department of Molecular Imaging and Therapy, Beckman Research Institute of the City of Hope, Duarte, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gary A. Ulaner

10Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jedd D. Wolchok

3Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York;

4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York;

5Department of Medicine, Weill Cornell Medical College, New York, New York;

11Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael A. Postow

4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York;

5Department of Medicine, Weill Cornell Medical College, New York, New York;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Neeta Pandit-Taskar

3Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York;

12Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and

13Department of Radiology, Weill Cornell Medical College, New York, New York

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 63, Issue 5

May 1, 2022

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of ⁸⁹Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody

Journal of Nuclear Medicine May 2022, 63 (5) 720-726; DOI: 10.2967/jnumed.121.262485

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of ⁸⁹Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody